WonderTx claims a spot in Y Combinator's Summer 2026 cohort, but the startup has no visible presence: no website, no SEC filings, no entry in the YC directory as of mid-August searches. The company appears to be operating in stealth, which is not unusual for early-stage health tech ventures navigating regulatory uncertainty and competitive pressure. What makes the timing intriguing is the market moment WonderTx has allegedly chosen to enter. Novo Nordisk and Eli Lilly both launched oral versions of their blockbuster GLP-1 drugs in the first half of this year, and JPMorgan's March 2026 analysis forecasts the global incretin market at $200 billion by 2030.
That figure reflects a profound shift in how pharmaceutical giants are approaching metabolic disease. For years, the promise of oral delivery for large molecules hovered somewhere between wishful thinking and expensive failure. Now the first wave of FDA-approved pills is sitting on pharmacy shelves, and the race to replace needles with tablets has moved from concept to commercial reality.
Pills Over Needles
Novo Nordisk's oral Wegovy pill cleared the FDA on December 22, 2025, for weight management. "The pill is here. With today's approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection," Mike Doustdar, the company's president and CEO, said at the time. By early May, Novo had rolled out an oral version of Ozempic in U.S. pharmacies, partnering with GoodRx to offer self-pay pricing at $149 per month, according to a May 1 announcement.
Eli Lilly moved faster with a chemically distinct approach. The FDA approved Foundayo in April under the agency's National Priority Voucher pilot program. The drug uses orforglipron, a true small molecule rather than a reformulated peptide. Lilly announced in May that both Foundayo and Zepbound, its injectable counterpart, now carry coverage from the three largest pharmacy benefit managers, a move that expands access to millions of Americans who previously faced high out-of-pocket costs or outright exclusions.
Morgan Stanley published a forecast in May placing the combined diabetes and obesity GLP-1 market at $190 billion by 2035, assuming penetration climbs to 30 percent of the U.S. obese and diabetic population versus 6 percent in 2025. Goldman Sachs took a more conservative view in a report from last year, trimming its 2030 global anti-obesity forecast to $95 billion but predicting that daily oral pills will capture roughly a quarter of that total by decade's end. The divergence in these estimates reflects uncertainty about durability, tolerability, and whether insurers will treat obesity drugs as chronic-care necessities or discretionary lifestyle aids.
Why Patients Want Pills
Patient preference plays a significant role in the shift. A study from 2020 found that 76.5 percent of people with type 2 diabetes preferred a once-daily oral medication over a once-weekly injection, though more recent preference data may differ as oral options have become available. An international survey overview from 2022 noted that needle phobia affects 20 to 30 percent of adults in the 20-to-40 age bracket; updated numbers may differ, and that figure may underestimate the psychological barrier for some patient groups.
Regulatory tailwinds have also cleared the path. The FDA declared the semaglutide injection shortage resolved in February 2025 and ended enforcement discretion for compounding pharmacies by May of that year, according to agency statements. In April of this year, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the bulk-substances list that allows outsourcing facilities to compound copies. Public comment on that proposal closed in late June. The move pushes demand toward FDA-approved branded pills and injectables, a shift that benefits the pharma giants but has drawn pushback from patient advocates concerned about affordability.
Artificial intelligence is entering formulation and peptide design in ways that could compress development timelines. A review published in Advanced Drug Delivery Reviews this past June discussed machine-learning-based dose prediction, formulation optimization, and digital manufacturing for oral drugs. A May preprint on arXiv described uncertainty-aware generative design of permeable cyclic peptides using conformal prediction and reinforcement learning, methodologies aimed at making large molecules orally bioavailable. A paper from last year in Frontiers in Bioinformatics reported that a new attention-transformer model outperformed earlier methods on standard permeability datasets for cyclic peptides.
Whether these tools will deliver marketed products faster than traditional chemistry, manufacturing, and controls workflows remains an open question.
Three Paths to Oral Delivery
Novo Nordisk acquired Emisphere Technologies in 2020 to secure SNAC, a permeation enhancer that coats peptides and allows stomach absorption. The company's oral semaglutide portfolio now spans three branded products: Rybelsus for type 2 diabetes, approved in 2019; the Wegovy pill for obesity, cleared this past December; and the Ozempic pill for diabetes with cardiovascular and kidney benefits, launched in May. All three rely on SNAC chemistry rather than device-mediated delivery, a distinction that matters for manufacturing scale and cost.
Eli Lilly's Foundayo uses a different path. Orforglipron is a small molecule, not a peptide reformulated with an enhancer. The FDA label, posted in April, notes no food or water restrictions, a dosing convenience that oral semaglutide's fasting requirements do not permit. Lilly presented additional Phase 3 results from the ATTAIN and ACHIEVE trials in May and June, showing weight-loss and diabetes outcomes that matched or exceeded earlier-generation injectables.
Not every pharma giant has succeeded. Pfizer halted a twice-daily formulation of danuglipron in November 2023 after Phase 2b tolerability issues. An extended-release, once-daily version entered dose optimization in April 2025 and remains in Phase 1, according to Pfizer's pipeline disclosures from earlier this year. The company has not offered a timeline for advancing the program, and some industry watchers question whether Pfizer will catch up to Lilly and Novo or quietly shelve the effort.
Device-mediated delivery offers a third route, one that sidesteps the chemistry challenges entirely. Rani Therapeutics operates RaniPill, a swallowable auto-injector that uses a spring-loaded microneedle to punch drug through the intestinal wall after a coating dissolves. The company's pipeline lists RT-114, a GLP-1/GLP-2 dual agonist in Phase 1 with partner ProGen, and RT-116, an oral semaglutide formulation in preclinical development. Rani says it holds more than 400 patent applications and claims bioavailability comparable to subcutaneous injection. "This is a first-of-its-kind innovation … to convert injectable drugs into pills," Mir Imran, then chairman and CEO, said in a 2019 announcement of first-in-human data.
Biora Therapeutics is advancing BioJet, another systemic swallowable auto-injector. The company announced platform progress on April 8. Biora also runs NaviCap, a colonic-targeting device; Phase 1 single-ascending-dose results for BT-600, a NaviCap formulation of tofacitinib, appeared in May 2024.
Entera Bio licensed its N-Tab permeation-enhancer platform to OPKO Health in March 2025 for an oral oxyntomodulin tablet targeting obesity. Entera said the collaboration aims for an IND filing in late first-half 2026. The company also submitted a Phase 3 protocol in February for EB613, an oral parathyroid hormone for osteoporosis.
Syntis Bio, working on therapies that target small-intestine biology, dosed its first patient with SYNT-101 for obesity on March 3 and released initial Phase 1/1b single-ascending-dose data in mid-July.
The Hard Cases
Oral insulin remains elusive, a reminder that not every large molecule will surrender to formulation tricks or device engineering. Novo Nordisk discontinued an oral insulin candidate, OI338GT, in 2016 for commercial-viability reasons, according to a company financial filing. Oramed Pharmaceuticals reported a Phase 3 failure for ORMD-0801 in January 2023; the company later explored subpopulation analyses and a joint venture with HTIT in 2024 and 2025, though concrete results have yet to emerge.
Academic labs are pushing device engineering in directions that may eventually bypass the formulation problem altogether. MIT and Novo Nordisk collaborated on SOMA and L-SOMA, ingestible capsules that use microneedles or jet propulsion to deliver insulin, GLP-1s, antibodies, and RNA into the gastric or intestinal wall. A Nature paper from last year and MIT News coverage described a bio-inspired jetting capsule that pumps drug payload directly through tissue, bypassing enzymatic breakdown and poor permeability. ARPA-H funded an MIT-led consortium in February 2024 to advance ingestible-device manufacturing and reliability for metabolic-disease treatments, according to an MIT announcement.
The work suggests that oral delivery of antibodies and nucleic acids is moving from concept to clinical proof, though the path to commercial scale remains uncertain.
What Comes Next
The oral-peptide and oral-protein market was valued at $7.9 billion in 2024 and is forecast to reach $25.9 billion by 2030, according to a Stratistics MRC report. A more recent roundup from this past spring estimates the broader peptide-therapeutics market at $60 billion to $75 billion by 2030.
Recent reviews suggest AI-driven formulation design has potential to compress development timelines, though real-world validation in manufacturing and clinical settings has yet to arrive. Reviews published over the past two years describe machine-learning workflows that integrate physiologically based pharmacokinetic modeling with formulation screening, allowing faster iteration on bioavailability and manufacturability. Generative models for cyclic-peptide design, detailed in the May arXiv preprint, use reinforcement learning to optimize membrane permeability while maintaining target affinity. The workflow could bypass years of empirical formulation work, though real-world validation in manufacturing and clinical settings has yet to arrive.
Device platforms will likely broaden beyond GLP-1s. Rani Therapeutics lists biosimilar programs for ustekinumab and adalimumab in Phase 1 and preclinical stages, targeting immunology indications that currently require injection or infusion. Biora's BioJet aims for systemic delivery of large molecules, and MIT's work extends to RNA payloads.
Payer dynamics remain a wildcard. Lilly said in May that major PBMs now cover Foundayo and Zepbound, a shift driven by clinical data and competitive pressure from Novo's oral and injectable portfolio. Morgan Stanley's $190 billion forecast assumes 30 percent penetration of the U.S. obese and diabetic population by 2035; Goldman Sachs' $95 billion estimate reflects skepticism about durability, tolerability, and reimbursement constraints. Actual uptake will hinge on whether oral options prove as effective and safe as injectables in real-world use, and whether employers and insurers treat obesity drugs as chronic-care necessities or optional lifestyle aids. That debate is already underway in corporate benefit committees and state Medicaid offices, and the outcome will shape the market as much as any clinical trial.
Founders and investors eyeing the space should watch three near-term milestones. Can AI-formulation tools deliver marketed products faster than traditional chemistry workflows? Will device-mediated oral delivery scale to antibodies and beyond GLP-1s? And will regulators and payers treat oral biologics as line extensions of existing injectables or as distinct therapeutic classes? The FDA's National Priority Voucher pilot, which accelerated Foundayo's April approval, signals an appetite for faster reviews of high-impact therapies, though the sustainability of that pathway under shifting political winds is anyone's guess.
The race to replace needles with pills is no longer speculative. The first wave landed in pharmacies this year, and the question now is whether the second wave will broaden the chemistry playbook, deepen device innovation, or simply refine what Novo and Lilly have already proven. WonderTx, wherever it is, has chosen a crowded and unforgiving moment to enter.
